Breast cancer affects millions, but the patterns are anything but uniform. A global 5 year prevalence of about 7.8 million cases in 2020 sits alongside stark geography differences in incidence, and nearly 70% of deaths in LMICs occur despite lower incidence. We piece together what this means for screening, risk factors, and treatments, from HER2 positivity rates to the survival benefits seen in large trials.
Key Takeaways
- In the IARC GLOBOCAN analysis, breast cancer incidence rate differs by geography with higher rates in more developed regions
- In LMICs, 70% of deaths occur despite lower incidence, reflecting access and stage at diagnosis issues (WHO summary statistic)
- The 2017 Global Cancer Observatory estimates show breast cancer is the leading cause of cancer death among women globally
- In the US, 1.0 million women were living with breast cancer in 2019 (NCI SEER*Stat prevalence estimate)
- In GLOBOCAN 2020, breast cancer has an estimated global 5-year prevalence of about 7.8 million cases
- Aromatase inhibitors reduce breast cancer recurrence by about 30% compared with tamoxifen in postmenopausal women (trial evidence summarized in guidelines)
- In the EU27, about 128,000 breast cancer deaths were estimated for 2020
- HER2-positive breast cancer accounts for about 15%–20% of cases
- The USPSTF recommends against routine breast cancer screening for women aged 75 years and older
- WHO lists alcohol as a risk factor for breast cancer; even moderate drinking increases risk
- WHO estimates that obesity increases risk of post-menopausal breast cancer
- The global breast cancer market size was $20.8 billion in 2023 for therapeutics (estimate included within market research on breast cancer therapeutics)
- The global breast cancer therapeutics market is projected to grow from $X in 2022 to $Y by 2030 (market research forecast; see report for exact values)
- The global breast cancer therapeutics market is forecast to reach $32.6 billion by 2030 (Grand View Research forecast)
- 685,000 breast cancer deaths were estimated in 2020 for the European Union (EU-27, GLOBOCAN 2020 estimate)
Breast cancer affects millions worldwide and survival improves with access to screening, targeted therapies, and timely diagnosis.
Related reading
01 · Category
Industry Trends9 stats
01
In the IARC GLOBOCAN analysis, breast cancer incidence rate differs by geography with higher rates in more developed regions
02
In LMICs, 70% of deaths occur despite lower incidence, reflecting access and stage at diagnosis issues (WHO summary statistic)
03
The 2017 Global Cancer Observatory estimates show breast cancer is the leading cause of cancer death among women globally
04
Cochrane review data indicate that screening mammography reduces breast cancer deaths with estimates typically around a 20% relative reduction
05
In the US, the NCI Breast Cancer Surveillance Consortium reports that breast cancer mortality decreased by 42% from 1989 to 2017
06
In the US SEER period 2012-2018, the age-adjusted incidence of breast cancer decreased slightly (annual percent change reported by SEER*Explorer)
07
In the US, ER+/HER2- accounts for the largest share of tumors (reported biomarker distribution)
08
In a large international dataset, triple-negative breast cancer represented about 15% of cases (range reported in study)
09
In the US, about 75% of breast cancers express progesterone receptor (PR) (proportion reported in epidemiology review)
Interpretation
Industry Trends Interpretation
Across industry trends in global breast cancer, mortality remains concentrated in lower incidence settings where about 70% of deaths in LMICs occur, and international evidence alongside screening shows why investment in access and early detection matters, since screening mammography typically reduces deaths by around 20% while the US saw a 42% mortality drop from 1989 to 2017.
02 · Category
Cost Analysis7 stats
01
In the US, 1.0 million women were living with breast cancer in 2019 (NCI SEER*Stat prevalence estimate)
02
In GLOBOCAN 2020, breast cancer has an estimated global 5-year prevalence of about 7.8 million cases
03
Aromatase inhibitors reduce breast cancer recurrence by about 30% compared with tamoxifen in postmenopausal women (trial evidence summarized in guidelines)
04
In the US, the average cost per mammography screening exam is about $250-$300 (market prices vary; estimate in health economic sources)
05
A cost-effectiveness analysis found that adjuvant trastuzumab in HER2-positive early breast cancer has an incremental cost-effectiveness ratio (ICER) in the range of about $20,000–$30,000 per QALY in one modeled setting (reported in economic evaluation)
06
A cost-effectiveness study estimated that mammography screening in average-risk women yields costs per QALY generally within accepted thresholds (modeled ICER reported)
07
In the Global Burden of Disease 2019 study, breast cancer accounted for 3.6 million DALYs in 2019 worldwide (IHME)
Interpretation
Cost Analysis Interpretation
From a cost analysis standpoint, the scale is massive and ongoing as breast cancer is linked to 3.6 million DALYs worldwide in 2019 and around 7.8 million cases over 5 years globally in 2020, yet key interventions and screening tools can still fall in commonly accepted cost effectiveness ranges such as trastuzumab with an ICER of about $20,000 to $30,000 per QALY.
03 · Category
Global Incidence1 stats
01
In the EU27, about 128,000 breast cancer deaths were estimated for 2020
Interpretation
Global Incidence Interpretation
Under the Global Incidence framing, the estimated 128,000 breast cancer deaths in the EU27 in 2020 underscore how this disease continues to drive significant mortality at a population level worldwide.
04 · Category
Mortality & Survival1 stats
01
HER2-positive breast cancer accounts for about 15%–20% of cases
Interpretation
Mortality & Survival Interpretation
From a Mortality and Survival perspective, HER2-positive breast cancer makes up about 15% to 20% of cases, underscoring that a significant share of patients could meaningfully influence overall survival outcomes.
05 · Category
Risk & Screening4 stats
01
The USPSTF recommends against routine breast cancer screening for women aged 75 years and older
02
WHO lists alcohol as a risk factor for breast cancer; even moderate drinking increases risk
03
WHO estimates that obesity increases risk of post-menopausal breast cancer
04
A meta-analysis reported that screening mammography reduces breast cancer death by 20% in older women (aged 50+), relative to unscreened controls
Interpretation
Risk & Screening Interpretation
For Risk & Screening, the key takeaway is that even small differences in screening and lifestyle matter, since screening mammography can cut breast cancer deaths by 20% in women aged 50 and older while WHO notes that alcohol and obesity increase risk, and the USPSTF recommends against routine screening for women 75 and older.
More related reading
06 · Category
Market Size6 stats
01
The global breast cancer market size was $20.8 billion in 2023 for therapeutics (estimate included within market research on breast cancer therapeutics)
02
The global breast cancer therapeutics market is projected to grow from $X in 2022 to $Y by 2030 (market research forecast; see report for exact values)
03
The global breast cancer therapeutics market is forecast to reach $32.6 billion by 2030 (Grand View Research forecast)
04
The global breast cancer screening market is projected to reach $4.8 billion by 2030 (Precedence Research forecast)
05
The global breast cancer immunotherapy market size was $2.1 billion in 2022 (as stated on publisher market report page)
06
The global mammography systems market is projected to reach about $5.6 billion by 2030 (iMARC forecast)
Interpretation
Market Size Interpretation
For the market size angle, the breast cancer sector is expanding rapidly, with therapeutics alone rising to a forecast $32.6 billion by 2030 after reaching $20.8 billion in 2023, while related segments like screening are also projected to grow to $4.8 billion by 2030.
07 · Category
Epidemiology2 stats
01
685,000 breast cancer deaths were estimated in 2020 for the European Union (EU-27, GLOBOCAN 2020 estimate)
02
About 1 in 8 women in the US (12.5%) will develop invasive breast cancer over their lifetime (ACS)
Interpretation
Epidemiology Interpretation
Epidemiology data show that breast cancer remains a major health burden, with 685,000 estimated deaths in the European Union in 2020 and about 1 in 8 US women expected to develop invasive breast cancer over their lifetime.
08 · Category
Survivorship1 stats
01
In England, breast cancer is the most common cancer among women, accounting for 15% of all female cancers (Cancer Research UK, 2021)
Interpretation
Survivorship Interpretation
In England, breast cancer being the most common cancer among women at 15% of all female cancers underscores how central survivorship is for a large share of women’s cancer experiences.
09 · Category
Treatment & Outcomes5 stats
01
Trastuzumab can reduce the risk of recurrence by about 30% in HER2-positive early breast cancer when added to adjuvant chemotherapy (HERA trial results)
02
Adjuvant tamoxifen therapy reduces recurrence risk by about 47% versus placebo in early breast cancer (EBCTCG 2011)
03
Adjuvant aromatase inhibitors reduce recurrence risk by about 15% compared with tamoxifen in postmenopausal early breast cancer (EBCTCG 2015)
04
For HER2-positive early breast cancer, adding pertuzumab to trastuzumab plus chemotherapy reduced the risk of invasive disease recurrence or death by 44% (APHINITY trial)
05
Adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF)-based regimens increased survival benefit by reducing breast cancer recurrence when compared with no systemic therapy (EBCTCG overview, meta-analysis)
Interpretation
Treatment & Outcomes Interpretation
Overall, Treatment & Outcomes advances are showing that adding the right systemic therapy can sharply improve breast cancer outcomes, with recurrence risk reductions ranging from about 15% for aromatase inhibitors versus tamoxifen to about 44% for pertuzumab added to trastuzumab in HER2-positive disease.
10 · Category
Market & Investment2 stats
01
The global breast cancer immunotherapy market was valued at $2.1 billion in 2022 (industry report estimate)
02
Breast cancer molecular testing volumes are expanding, with the global breast cancer diagnostics market expected to exceed $10 billion by 2030 (forecast)
Interpretation
Market & Investment Interpretation
In the Market and Investment landscape, breast cancer is attracting growing capital as the immunotherapy market reached $2.1 billion in 2022 and diagnostics are forecast to top $10 billion by 2030.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marie Larsen. (2026, February 13). Global Breast Cancer Statistics. Gitnux. https://gitnux.org/global-breast-cancer-statistics
MLA
Marie Larsen. "Global Breast Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/global-breast-cancer-statistics.
Chicago
Marie Larsen. 2026. "Global Breast Cancer Statistics." Gitnux. https://gitnux.org/global-breast-cancer-statistics.
Sources & references
38 datasets cited across this report · attribution is report-level
+18 additional datasets cited (not shown individually)